Search

Search Constraints

You searched for: Author/Creator Palla, Marco

Search Results

1. Correlation between BRAF mutational status and clinical response to pembrolizumab in advanced melanoma patients. (4th November 2015)

2. Correlation between BRAF mutational status and clinical response to pembrolizumab in advanced melanoma patients. Issue 2 (December 2015)

3. Correlation between immune-related adverse events and response to pembrolizumab in advanced melanoma patients. (4th November 2015)

4. Correlation between immune-related adverse events and response to pembrolizumab in advanced melanoma patients. Issue 2 (December 2015)

5. Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma. (4th March 2017)

7. Long-term vemurafenib therapy in advanced melanoma patients: cutaneous toxicity and prognostic implications. (3rd April 2022)

9. Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy. Issue 2 (11th August 2020)

10. Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy. Issue 2 (11th August 2020)